Home / Brand archive
240 reported ongoing
258 records in this archive. Latest source date Sep 3, 2026. 4 published notices do not supply a closure status.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
The potential for the needle tip to be dull/blunt, difficult to advance, and/or break.
Class IIReported ongoing
Distribution: Worldwide - US Nationwide distribution in the state of TX and the country of Costa Rica.
The potential for the needle tip to be dull/blunt, difficult to advance, and/or break.
Class IIReported ongoing
Distribution: Worldwide - US Nationwide distribution in the state of TX and the country of Costa Rica.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
B. Braun was notified by our supplier, Ferndale Laboratories, Inc., the manufacturer of MASTISOL¿ Liquid Adhesive, that they have issued a voluntary recall due to potential cracking of the butyrate tubing (outside tube), which renders the product unusable.
Class IIReported ongoing
Distribution: US Nationwide distribution in the states of AL, FL, PA, TX, VA, WA.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class IIReported ongoing
Distribution: Worldwide distribution - US distribution and international distribution to Canada, Germany, Guatemala, and Singapore.
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 258 records, including 240 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.